Tudor Investment Corp ET AL Takes $1.35 Million Position in Celcuity, Inc. $CELC

Key Points

• Tudor Investment Corp opened a new position in Celcuity in Q3, buying 27,340 shares valued at about $1.35 million, roughly 0.06% of the company.
• Celcuity has a market cap near $5.82 billion, a one-year trading range of $9.02–$125.00 and negative EPS (analysts forecast -2.62 for the year), while the consensus rating is a Moderate Buy with a $109.88 target.
• Insiders have trimmed holdings recently (Director David Dalvey sold 20,000 shares for about $2.4M; Director Richard Buller sold 3,000 shares), with insiders owning 15.77% and institutions 63.33% of the stock.

Tudor Investment Corp ET AL bought a new position in Celcuity, Inc. (NASDAQ:CELC - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 27,340 shares of the company's stock, valued at approximately $1,351,000. Tudor Investment Corp ET AL owned about 0.06% of Celcuity as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV acquired a new stake in Celcuity in the 3rd quarter worth approximately $27,000. US Bancorp DE lifted its holdings in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after purchasing an additional 143 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Celcuity by 611.2% in the 3rd quarter. Versant Capital Management Inc now owns 1,593 shares of the company's stock worth $79,000 after purchasing an additional 1,369 shares during the last quarter. Avanza Fonder AB acquired a new stake in Celcuity in the 3rd quarter worth approximately $79,000. Finally, BNP Paribas Financial Markets lifted its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after purchasing an additional 1,167 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

CELC opened at $120.40 on Tuesday. The stock has a market cap of $5.82 billion, a PE ratio of -31.77 and a beta of 0.41. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. Celcuity, Inc. has a 1 year low of $9.02 and a 1 year high of $125.00. The stock's 50 day simple moving average is $110.50 and its 200-day simple moving average is $95.96.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.09. Sell-side analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CELC shares. Needham & Company LLC restated a "buy" rating and issued a $122.00 target price on shares of Celcuity in a report on Thursday, March 26th. Stifel Nicolaus lifted their price target on Celcuity from $115.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. Wolfe Research reaffirmed an "outperform" rating and issued a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Wall Street Zen raised Celcuity from a "sell" rating to a "hold" rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celcuity in a research report on Wednesday, January 21st. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $109.88.

Insiders Place Their Bets

In other Celcuity news, Director David Dalvey sold 20,000 shares of the company's stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard E. Buller sold 3,000 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the completion of the sale, the director owned 6,760 shares in the company, valued at $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.77% of the company's stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.